Table 3.
Patients With an Unfavorable Change Beyond Minimal Clinical Important Difference in the Fatigue Score at the 12-Month Follow-up Compared to All Other Patients (N = 51)
| Variable | Unfavorable Change Beyond MCID in Fatigue Score at 12-Month Follow-up (N = 17) |
All Other Patients (N = 34) |
P-value |
|---|---|---|---|
| Age at surgery, mean (SD) | 45.8 (11.5) | 41.5 (12.1) | .25 |
| Female, No (%) | 6 (35.3) | 20 (58.8) | .14 |
| KPS < 80 at admission, No (%) | 1 (5.9) | 5 (14.7) | .65 |
| Incidental, No (%) | 2 (11.8) | 6 (17.6) | .70 |
| History of seizures at admission, No (%) | 12 (70.6) | 22 (64.7) | .76 |
| Any neurological deficit at admission, No (%) | 5 (29.4) | 10 (29.4) | 1.0 |
| History of seizures at admission without any neurological deficit, No (%) | 10 (58.8) | 15 (44.1) | .38 |
| Tumor location, No (%) | |||
| Mainly frontal | 11 (64.7) | 18 (52.9) | .55 |
| Mainly temporal | 3 (17.6) | 6 (17.6) | 1.0 |
| Other | 3 (17.6) | 10 (29.4) | .50 |
| Tumor laterality, mainly left hemisphere, No (%) | 7 (41.2) | 16 (47.1) | .77 |
| Choice of neurosurgical intervention, No (%) | |||
| Tumor resection | 16 (94.1) | 32 (94.1) | 1.0 |
| Tumor type, oligodendroglioma, No (%) | 11 (64.7) | 15 (44.1) | .24 |
| Tumor grade, grade 2, No (%) | 9 (52.9) | 24 (70.6) | .23 |
| Treatment before 12-month follow-up | |||
| Start chemotherapy (delta T in months), mean (SD) | 5.1 (2.6) | 4.0 (2.1) | .18 |
| Start radiotherapy (delta T in months), mean (SD) | 3.7 (2.6) | 3.4 (2.5) | .72 |
| None, No (%) | 2 (11.8) | 6 (17.6) | .70 |
| Chemotherapy onlya, No (%) | 0 (0) | 5 (14.7) | .16 |
| Radiochemotherapya,b, No (%) | 15 (88.2) | 23 (67.6) | .18 |
| Other treatment details | |||
| Choice of chemotherapy first line drugs, temozolomide, No/N (%) | 6/15 (40.0) | 19/28 (67.9) | .11 |
| Radiation type, proton, No/N (%) | 10/15 (66.7) | 22/23 (95.7) | .03 (*) |
| Radiation mean dose to the brain, GyRBEc, mean (SD) | 14.9 (5.7) | 13.6 (4.5) | .48 |
| Other relevant treatments and interventions, No/N (%) | |||
| Antiepileptic drug use at 12-month follow-up* | 12/15 (80.0) | 21/31 (67.7) | 0.50 |
| Physical rehabilitation* | 3/16 (18.8) | 6/34 (17.6) | 1.0 |
| Any permanent, new or worsened, neurological deficit, No (%) | 4 (23.5) | 8 (23.5) | 1.0 |
aEither temozolomide, lomustine or procarbazine hydrochloride, lomustine and vincristine (PCV).
bEither concomitant or adjuvant.
cBiologic equivalent dose with fractions of 2Gy (α/β3).
*Observe missing data.
(*)Observe that only 6 patients received photon-therapy compared to 32 receiving proton therapy.